Q-omics provides the consensus-scored CLEC14A profile across patient tissues and cancer cell-line models. CLEC14A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLEC14A is differentially expressed in 16, with the highest sampling consensus in LUAD. Additionally, CLEC14A RNA expression shows 23,000 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where CLEC14A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC14A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC14A survival associations across molecular data types. CLEC14A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC14A RNA expression–survival associations across cancer types. High CLEC14A expression shows unfavorable associations in UVM, KIRP, LUSC and MESO, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLEC14A RNA expression.
This table summarizes CLEC14A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CLEC14A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC14A shows lower tumor expression in LUAD, KICH, LUSC, BLCA and KIRP and higher tumor expression in KIRC. The LUAD box plot shows higher CLEC14A RNA expression in normal versus tumor tissue (log2 FC = −2.790, t-test p < 0.001).
This table shows molecular features associated with CLEC14A in patient tissues and cancer cell lines. In patient samples, CLEC14A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC14A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and CNS.
